Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.2793 -0.0107 (-3.69%)
Streaming Delayed Price Updated: 2:23 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
Via Investor Brand Network
Why Psychedelics Could Soon Replace Antidepressants
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... 
Via FinancialNewsMedia
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
From Cybin Inc.
Via Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position of Psychedelic Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space
Via Investor Brand Network
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
From Cybin Inc.
Via Business Wire
Cybi (NEO: CYBN) (NYSE American: CYBN) to Participate in Benzinga Psychedelics Conference
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference
Via Investor Brand Network
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Study
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development
Via Investor Brand Network
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone in CYB003 Program
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program
Via Investor Brand Network
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,... 
Via FinancialNewsMedia
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
From Cybin Inc.
Via Business Wire
Cybin (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology
Via Investor Brand Network
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
From Cybin Inc.
Via Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.